Clinical trial

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00097760

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Natalizumab Normalized identity: natalizumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-06-01

PhasePHASE2

Conditions

Multiple Sclerosis, Relapsing-Remittingunresolved

Interventions

NatalizumabDRUG · verified · RxNorm: natalizumab

PlaceboDRUG

Sponsors & collaborators

Biogenlead sponsor

Elan Pharmaceuticalscollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00097760 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.